US Stock MarketDetailed Quotes
ATHE Alterity Therapeutics
- 1.2500
- -0.0097-0.77%
Close Oct 16 16:00 ET
- 1.2500
- 0.00000.00%
Post 20:02 ET
10.93MMarket Cap-600P/E (TTM)
1.2600High1.2200Low6.24KVolume1.2600Open1.2597Pre Close7.77KTurnover0.09%Turnover RatioLossP/E (Static)8.74MShares5.410052wk High1.19P/B8.45MFloat Cap1.010052wk Low--Dividend TTM6.76MShs Float51.5000Historical High--Div YieldTTM3.18%Amplitude1.0100Historical Low1.2440Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Alterity Therapeutics Stock Forum
11/10/2024 - 19:35
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented a...
Alterity Therapeutics Announced Positive Interim Data From The ATH434-202 Open-label Phase 2 Clinical Trial In Patients With Multiple System Atrophy
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
▪️43% of participants showed improvement in daily living activities
29% had stable or improved neurological symptoms
▪️Objective biomarkers demonstrated improvement consist...
No comment yet